Abstract:Objective To evaluate the clinical efficacy and safety of iMliximab (IFX) in the treatment of Crohn's disease (CD).Methods From February 2009 to March 2013,the clinical data of 62 CD patients with IFX treatment were retrospectively analyzed.At week 14th after IFX injection and the end of follow-up of this study (March 2013) were two observation points.At week 14th after IFX injection (three times of IFX injection),C reactive protein (CRP) level,Crohn's disease activity index (CDAI) score and clinical remission were investigated.At the end of follow-up,clinical remission,fistula closure,mucosal healing and side effects were inspected.Normal distribution data were expressed as 2±s,which were compared with t test.Non normal distribution data were expressed as M (QL-QU) and compared with Wilcoxon test.Results Four cases without complete three times of IFX injection and one case lost to follow-up were eliminated.And nine postoperation cases with IFX treatment to prevent recurrence after surgery were excluded.A total of 48 cases of CD in active period were enrolled in this study on efficacy.At week 14th,CRP level of 48 patients [1.9(0.5,5.4) mg/L]decreased compared with that before treatment [28.9(6.4,51.1) mg/L] (Z=-5.468,P＜0.01);CDAI score (87.0±35.8) also decreased compared with that before treatment (245.1±59.1) (t=18.579,P＜0.01).At week 14th,46 patients in active period achieved clinical remission and the remission rate was 95.8％.By the end of follow-up,38 patients were still in remission period and the remission rate was 79.2％.Among 26 patients with anal fistula before IFX treatment,seven cases (26.9％) were completely closed,17 cases (65.4％) was partially closed and two cases was responseless.Fifteen patients were reviewed by colonoscopic examination after more than six times of IFX treatment.The median of simple endoscopic score for Crohn's disease (SES-CD) was 3 (0,5)after treatment,which decreased compared with that before treatment (8(7,9),Z=-3.306,P=0.001).Twenty-two of 48 cases in active period received,step-up strategy and 26 cases received with top-down strategy.At week 14th,20 cases (90.9％) of group with step-up strategy and 26 cases (100.0％) of group with top-down strategy were in remission period.By the end of follow-up,14 cases (63.6％) of group with step-up strategy and 24 cases (92.3％) of group with top down strategy maintained remission.Among 26 cases with anal fistula,two cases without response were treated with step-up strategy and seven cases with complete closure were all with top-down strategy.Among 62 patients,five had side effects,three of whom had acute infusion reaction,one had delayed infusion reaction and the other had anemia.Conclusions IFX had good clinical efficacy in controlling inflammation,inducing clinical remission,promoting fistula closure and mucosal healing in CD patients.For some CD patients with high risk,the initial top-down strategy showed good clinical efficacy.

Infliximab Reduces Cd147, Mmp-3, and Mmp-9 Expression in Peripheral Blood Monocytes in Patients with Active Rheumatoid Arthritis

Infliximab reduces the expression of CD147 on the peripheral CD14+ monocytes of active rheumatoid arthritis patients

Matrix metalloproteinase-3 and-9 : possible biomarkers of infliximab efficacy in ankylosing spondylitis ( AS ) ?

[Platelet Count Predicts Therapeutic Response of Infliximab for Active Crohn's Disease].

Effects of Infliximab Induced Clinical Remission of Active Crohn's Disease on the Level of Interleukin-21 and Interleukin-21 Receptor

Inhibitory Effect of Cd147/Hab18 Monoclonal Antibody on Cartilage Erosion and Synovitis in the Scid Mouse Model for Rheumatoid Arthritis

Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn’s Disease with Luminal Lesions Through Balancing Abnormal Immune Response in Gut Mucosa

Risk of Tuberculosis During Infliximab Therapy for Inflammatory Bowel Disease, Rheumatoid Arthritis, and Spondyloarthropathy: A Meta-Analysis

Infliximab Versus Placebo in Rheumatoid Arthritis Patients Receiving Concomitant Methotrexate: a Preliminary Study from China

Abberant CD200/CD200R1 Pathway Contribute to the Immunopathogenesis of Rheumatoid Arthritis

Expression of CD147 on Monocytes/macrophages in Rheumatoid Arthritis: Its Potential Role in Monocyte Accumulation and Matrix Metalloproteinase Production

CD147 overexpression on synoviocytes in rheumatoid arthritis enhances matrix metalloproteinase production and invasiveness of synoviocytes

[Efficacy and Safety of Infliximab in Patients with Rheumatoid Arthritis].

CD147 Induces Angiogenesis Through a Vascular Endothelial Growth Factor and Hypoxia-Inducible Transcription Factor 1Α-Mediated Pathway in Rheumatoid Arthritis.

Clinical efficacy of infliximab in the treatment of 62 cases with Crohn's disease

Association of short-term efficacy for infliximab in rheumatoid arthritis with plasma concentration and anti-drug antibody

Identifying Infliximab- (IFX-) Responsive Blood Signatures for the Treatment of Rheumatoid Arthritis

Good Response to Infliximab in Rheumatoid Arthritis Following Failure of Interleukin-1 Receptor Antagonist

CD147 Promotes IKK/IκB/NF-κB Pathway to Resist TNF-induced Apoptosis in Rheumatoid Arthritis Synovial Fibroblasts

Inhibiting Effects of Leflunomide Metabolite on Overexpression of CD147, MMP-2 and MMP-9 in PMA Differentiated THP-1 Cells.

Abatacept downregulates Fcγ receptor I on circulating monocytes: a potential therapeutic mechanism in patients with rheumatoid arthritis